BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 37623002)

  • 21. Development and Validation of Web-Based Nomograms to Precisely Predict Survival Outcomes of Non-metastatic Nasopharyngeal Carcinoma in an Endemic Area.
    Yao JJ; Lin L; Gao TS; Zhang WJ; Lawrence WR; Ma J; Sun Y
    Cancer Res Treat; 2021 Jul; 53(3):657-670. PubMed ID: 33285052
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A multidimensional nomogram combining overall stage, dose volume histogram parameters and radiomics to predict progression-free survival in patients with locoregionally advanced nasopharyngeal carcinoma.
    Yang K; Tian J; Zhang B; Li M; Xie W; Zou Y; Tan Q; Liu L; Zhu J; Shou A; Li G
    Oral Oncol; 2019 Nov; 98():85-91. PubMed ID: 31569054
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Integrating Baseline Nutritional and Inflammatory Parameters with Post-Treatment EBV DNA Level to Predict Outcomes of Patients with De Novo Metastatic Nasopharyngeal Carcinoma Receiving Chemotherapy Combination PD-1 Inhibitor.
    Guo J; Yang Q; Jiang Q; Gu LW; Lin HX; Guo L
    Nutrients; 2023 Oct; 15(19):. PubMed ID: 37836546
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A new prognostic model for predicting outcomes of patients with recurrent or metastatic nasopharyngeal carcinoma receiving subsequent line (≥2 lines) anti-programmed death-1 monotherapy.
    Li SC; Deng SW; Sun XS; Lan KQ; Guo CY; Lin DF; Liu LT; Liu SL; Mai HQ; Tang LQ
    Oral Oncol; 2023 Apr; 139():106336. PubMed ID: 36827901
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Establishment and validation of a nomogram for predicting the benefit of concurrent chemotherapy in stage II nasopharyngeal carcinoma: A study based on a phase III randomized clinical trial with 10-year follow-up.
    Sun XS; Li XY; Xiao BB; Liu SL; Chen QY; Tang LQ; Mai HQ
    Oral Oncol; 2020 Jan; 100():104490. PubMed ID: 31790913
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dynamic serum biomarkers to predict the efficacy of PD-1 in patients with nasopharyngeal carcinoma.
    Zhang A; Zhong G; Wang L; Cai R; Han R; Xu C; Chen S; Sun P; Chen H
    Cancer Cell Int; 2021 Sep; 21(1):518. PubMed ID: 34583688
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A nomogram model based on pre-treatment and post-treatment MR imaging radiomics signatures: application to predict progression-free survival for nasopharyngeal carcinoma.
    Sun MX; Zhao MJ; Zhao LH; Jiang HR; Duan YX; Li G
    Radiat Oncol; 2023 Apr; 18(1):67. PubMed ID: 37041545
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development and validation of a gene expression-based signature to predict distant metastasis in locoregionally advanced nasopharyngeal carcinoma: a retrospective, multicentre, cohort study.
    Tang XR; Li YQ; Liang SB; Jiang W; Liu F; Ge WX; Tang LL; Mao YP; He QM; Yang XJ; Zhang Y; Wen X; Zhang J; Wang YQ; Zhang PP; Sun Y; Yun JP; Zeng J; Li L; Liu LZ; Liu N; Ma J
    Lancet Oncol; 2018 Mar; 19(3):382-393. PubMed ID: 29428165
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of a Nomogram Model for Treatment of Nonmetastatic Nasopharyngeal Carcinoma.
    Zhang LL; Xu F; Song D; Huang MY; Huang YS; Deng QL; Li YY; Shao JY
    JAMA Netw Open; 2020 Dec; 3(12):e2029882. PubMed ID: 33306119
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Construction and Validation of a Novel Nomogram to Predict the Overall Survival of Patients With Combined Small Cell Lung Cancer: A Surveillance, Epidemiology, and End Results Population-Based Study.
    Jiang A; Liu N; Zhao R; Liu S; Gao H; Wang J; Zheng X; Ren M; Fu X; Liang X; Tian T; Ruan Z; Yao Y
    Cancer Control; 2021; 28():10732748211051228. PubMed ID: 34632799
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Establishment and validation of a nomogram with intratumoral heterogeneity derived from
    Gu B; Zhang J; Ma G; Song S; Shi L; Zhang Y; Yang Z
    BMC Cancer; 2020 Jan; 20(1):37. PubMed ID: 31941465
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Developing a nomogram model and prognostic analysis of nasopharyngeal squamous cell carcinoma patients: a population-based study.
    Liu K; Wang J
    J Cancer Res Clin Oncol; 2023 Oct; 149(13):12165-12175. PubMed ID: 37428250
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic score models for survival of nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy and chemotherapy.
    Zeng L; Guo P; Li JG; Han F; Li Q; Lu Y; Deng XW; Zhang QY; Lu TX
    Oncotarget; 2015 Nov; 6(36):39373-83. PubMed ID: 26415223
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of a prognostic model to identify the metastatic nasopharyngeal carcinoma patients who may benefit from chemotherapy combination PD-1 inhibitor.
    Liu GY; Lu N; Bei WX; Li WZ; Liang H; Xia WX; Xiang YQ; Yao HR
    Front Immunol; 2023; 14():1069010. PubMed ID: 36733479
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Establishment and validation of a novel nomogram to predict overall survival after radical nephrectomy].
    Xiong LB; Zou XP; Ning K; Luo X; Peng YL; Zhou ZH; Wang J; Li Z; Yu CP; Dong P; Guo SJ; Han H; Zhou FJ; Zhang ZL
    Zhonghua Zhong Liu Za Zhi; 2023 Aug; 45(8):681-689. PubMed ID: 37580273
    [No Abstract]   [Full Text] [Related]  

  • 36. Nomogram to Predict Long-Term Overall Survival and Cancer-Specific Survival of Radiotherapy Patients with Nasopharyngeal Carcinoma.
    Li Z; Li C; Yang D; Zhou Z; Kang M
    Biomed Res Int; 2023; 2023():7126881. PubMed ID: 36704722
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development and validation of a nomogram for predicting long-term overall survival in nasopharyngeal carcinoma: A population-based study.
    Wu J; Zhou Q; Pan Z; Wang Y; Hu L; Chen G; Wang S; Lyu J
    Medicine (Baltimore); 2020 Jan; 99(4):e18974. PubMed ID: 31977914
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel nomogram for predicting survival in advanced non-small cell lung cancer receiving anti-PD-1 plus chemotherapy with or without antiangiogenic therapy.
    Wu Y; Lv C; Lin M; Hong Y; Du B; Yao N; Zhu Y; Ji X; Li J; Lai J
    Front Immunol; 2023; 14():1297188. PubMed ID: 38022521
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumor residue in patients with stage II-IVA nasopharyngeal carcinoma who received intensity-modulated radiation therapy: development and validation of a prediction nomogram integrating postradiotherapy plasma Epstein-Barr virus deoxyribonucleic acid, clinical stage, and radiotherapy dose.
    Huang YY; Zhou JY; Zhan ZJ; Ke LR; Xia WX; Cao X; Cai ZC; Deng Y; Chen X; Zhang LL; Huang HY; Guo X; Lv X
    BMC Cancer; 2023 May; 23(1):410. PubMed ID: 37149594
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic nomograms for nasopharyngeal carcinoma with nodal features and potential indication for N staging system: Validation and comparison of seven N stage schemes.
    Peng WS; Xing X; Li YJ; Ding JH; Mo M; Xu TT; Zhou X; Hu CS
    Oral Oncol; 2023 Sep; 144():106438. PubMed ID: 37437499
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.